Exane Derivatives Aurinia Pharmaceuticals Inc. Transaction History
Exane Derivatives
- $157 Million
- Q2 2022
A detailed history of Exane Derivatives transactions in Aurinia Pharmaceuticals Inc. stock. As of the latest transaction made, Exane Derivatives holds 8,683 shares of AUPH stock, worth $70,071. This represents 0.06% of its overall portfolio holdings.
Number of Shares
8,683
Previous 8,683
-0.0%
Holding current value
$70,071
Previous $107,000
18.69%
% of portfolio
0.06%
Previous 0.03%
Shares
8 transactions
Others Institutions Holding AUPH
# of Institutions
208Shares Held
58.6MCall Options Held
1.14MPut Options Held
1.51M-
Black Rock Inc. New York, NY9.27MShares$74.8 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY8.2MShares$66.2 Million1.0% of portfolio
-
Tang Capital Management LLC San Diego, CA7.23MShares$58.3 Million4.52% of portfolio
-
Nea Management Company, LLC Timonium, MD3.97MShares$32 Million2.22% of portfolio
-
State Street Corp Boston, MA2.95MShares$23.8 Million0.0% of portfolio
About Aurinia Pharmaceuticals Inc.
- Ticker AUPH
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 141,892,000
- Market Cap $1.15B
- Description
- Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...